Home>Topics>Stocks>Theravance

Theravance THRX

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. Triple combo COPD therapy commences

      Headlines

      Wed, 16 Jul 2014

      Glaxo (NYSE: GSK ) and Theravance (NASDAQ: THRX ) start a Phase 3 clinical trial evaluating the safety and efficacy of the "closed" triple combination of FF/UMEC/VI in patients

    2. BRIEF-GSK, Theravance start phase III testing on COPD drug

      Headlines

      Wed, 16 Jul 2014

      * And theravance announce initiation of phase iii programme with fixed dose triple combination treatment ff/umec/vi in patients with copd Source text for Eikon: Further company coverage:

    3. Stocks To Watch: Apple, BlackBerry, United Continental...

      Headlines

      Fri, 11 Jul 2014

      Once the market opens, you can track how today's "Stocks To Watch" are performing here . To send in your own ideas for Monday's Stocks To Watch, email stockstowatch@seekingalpha.com before 6:00 AM ET Monday. Apple ( AAPL ) – short – Anthony Ruben The Wall Street Journal reports today that China’s

    4. Anoro Ellipta cleared in Australia

      Headlines

      Wed, 9 Jul 2014

      Australia's Therapeutic Goods Administration approves Glaxo ( GSK ) and Theravance 's ( THRX ) Anoro Ellipta (emeclidinium/vilanterol) for the treatment of symptoms in adult patients with chronic obstructive pulmonary

    5. GlaxoSmithKline Is Moving Forward After Woeful Performance

      Headlines

      Tue, 8 Jul 2014

      By Options Calling : GlaxoSmithKline ( GSK ) has been undergoing some significant restructuring over the recent past in a bid to cement its position in various core operations. The company has formed key partnerships in the production of various drugs, as it seeks to establish vibrant access to ...

    6. Anoro Ellipta cleared in Japan

      Headlines

      Fri, 4 Jul 2014

      and Welfare approves GlaxoSmithKline ( GSK ) and Theravance 's ( THRX ) Anoro Ellipta ( umeclidinium/vilanterol ) for ..... of the companies' 2002 collaboration agreement, Theravance is obligated to pay Glaxo a milestone payment of

    7. BRIEF-GSK and Theravance says gains approval in Japan for Anoro Ellipta

      Headlines

      Fri, 4 Jul 2014

      * Press_release:anoro ellipta(umeclidinium/vilant erol) gains approval in Japan for the treatment of COPD

    8. Glaxo earns $15M milestone from Theravance

      Headlines

      Wed, 2 Jul 2014

      The launch of Anoro (umeclidinium/vilanterol) in the U.K. triggers a $15M milestone payment from Theravance ( THRX ) to GlaxoSmithKline ( GSK ). Anoro is a once-daily bronchodilator for the treatment of symptoms in adults with

    9. BRIEF-GSK, Theravance submit sNDA to U.S. FDA for Breo Ellipta

      Headlines

      Mon, 30 Jun 2014

      * GSK and Theravance announce submission to US regulatory authorities for Fluticasone Furoate/Vilanterol in asthma

    10. Ad Comm recommendation bodes well for opioid-induced constipation drugs

      Headlines

      Thu, 12 Jun 2014

      the FDA, would potentially mitigate a time-consuming and expensive hurdle for the drug makers in their NDA application efforts. Related tickers: ( CBST -0.6% ) ( NKTR ) ( SLXP +3.2% ) ( THRX -2.4% ) ( PGNX ) Post your comment!

    « Prev12345Next »
    Content Partners